Trexquant Investment LP purchased a new stake in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 18,348 shares of the biotechnology company’s stock, valued at approximately $483,000.

Other large investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. boosted its position in Momenta Pharmaceuticals by 3.4% during the first quarter. Principal Financial Group Inc. now owns 638,832 shares of the biotechnology company’s stock valued at $11,595,000 after purchasing an additional 21,142 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Momenta Pharmaceuticals in the second quarter valued at approximately $936,000. Amalgamated Bank lifted its position in shares of Momenta Pharmaceuticals by 16.1% in the second quarter. Amalgamated Bank now owns 12,544 shares of the biotechnology company’s stock valued at $257,000 after buying an additional 1,739 shares during the last quarter. Aperio Group LLC lifted its position in shares of Momenta Pharmaceuticals by 17.0% in the second quarter. Aperio Group LLC now owns 21,371 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,102 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Momenta Pharmaceuticals in the second quarter valued at approximately $2,600,000. Institutional investors and hedge funds own 95.71% of the company’s stock.

Shares of NASDAQ MNTA opened at $11.17 on Thursday. The company has a market cap of $877.52 million, a PE ratio of -9.31 and a beta of 2.31. Momenta Pharmaceuticals, Inc. has a 1-year low of $11.11 and a 1-year high of $32.20.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.18. Momenta Pharmaceuticals had a negative return on equity of 44.72% and a negative net margin of 158.21%. The company had revenue of $14.88 million for the quarter, compared to analyst estimates of $16.99 million. During the same quarter last year, the company earned ($0.44) earnings per share. The firm’s quarterly revenue was down 38.2% compared to the same quarter last year. On average, research analysts expect that Momenta Pharmaceuticals, Inc. will post -2.69 EPS for the current year.

In other Momenta Pharmaceuticals news, CEO Craig A. Wheeler sold 4,374 shares of the firm’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $13.50, for a total value of $59,049.00. The sale was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders sold 8,136 shares of company stock worth $106,026. Company insiders own 4.80% of the company’s stock.

A number of analysts have recently issued reports on MNTA shares. Cantor Fitzgerald set a $24.00 price objective on Momenta Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, October 10th. ValuEngine lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday. BidaskClub lowered Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Piper Jaffray Companies started coverage on Momenta Pharmaceuticals in a research note on Monday, November 5th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Monday, October 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $27.00.

COPYRIGHT VIOLATION NOTICE: “18,348 Shares in Momenta Pharmaceuticals, Inc. (MNTA) Purchased by Trexquant Investment LP” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/18348-shares-in-momenta-pharmaceuticals-inc-mnta-purchased-by-trexquant-investment-lp/2665404.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Featured Story: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.